Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AVPR2 | P30518 | 4/20 | 0.46 |
| ▸ | FFAR2 | O15552 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | AVPR1A | P37288 | 2/20 | 0.41 |
| ▸ | OXTR | P30559 | 1/20 | 0.41 |
| ▸ | HTR1D | P28221 | 2/20 | 0.40 |
| ▸ | HTR1B | P28222 | 2/20 | 0.40 |
| ▸ | CDK4 | P11802 | 1/20 | 0.40 |
| ▸ | CCND1 | P24385 | 1/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142035 | 0.87 | AVPR2 (0.55) | AVPR2KMT2AAVPR1AOXTRHTR1D | |
| SCHEMBL4140577 | 0.87 | AVPR2 (0.48) | AVPR2FFAR2MEN1POLBKMT2A | |
| SCHEMBL4144847 | 0.86 | AVPR2 (0.52) | AVPR2POLBKMT2AAVPR1AOXTR | |
| SCHEMBL4137666 | 0.85 | AVPR2 (0.61) | AVPR2POLBAVPR1AALDH1A1GAA | |
| Formaldehyde SCHEMBL6355613 | 0.84 | AVPR2 (0.51) | AVPR2POLBKMT2AAVPR1AOXTR | |
| SCHEMBL4141160 | 0.83 | AVPR2 (0.47) | AVPR2MEN1KMT2ACDK4CCND1 | |
| SCHEMBL5118133 | 0.78 | AVPR2 (0.47) | AVPR2FFAR2MEN1POLBKMT2A | |
| SCHEMBL4150860 | 0.73 | AVPR2 (0.61) | AVPR2MEN1KMT2AAVPR1AALDH1A1 | |
| SCHEMBL3538425 | 0.73 | AVPR1A (0.76) | AVPR2AVPR1A | |
| SCHEMBL4150438 | 0.72 | AVPR2 (0.66) | AVPR2AVPR1AOXTR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465722-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2008-12-16 | — | — | US | claimed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | claimed |
| US-20060276456-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2006-12-07 | — | — | US | claimed |
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7465722-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7223752-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060276456-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | disclosed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | AVPR2, AVPR1B, SSTR3 | AVPR2 1/4885FFAR2 423/4885MEN1 427/4885 |
| US-20060276456-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | AVPR2 1/4885FFAR2 423/4885MEN1 427/4885 |
| US-20050075328-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | AVPR2 1/4885FFAR2 423/4885MEN1 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.